Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Journal of clinical lipidology Année : 2018

Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia

Résumé

We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
Fichier principal
Vignette du fichier
case Report anti LPL antibodies Béliard -Valero.pdf (550.09 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01996207 , version 1 (28-01-2019)

Identifiants

Citer

Sophie Béliard, Mathilde Di Filippo, Gilles Kaplanski, Rene Valero. Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia. Journal of clinical lipidology, 2018, 12 (4), pp.883-887. ⟨10.1016/j.jacl.2018.04.011⟩. ⟨hal-01996207⟩
66 Consultations
270 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More